Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.31M$4.31Mderived−1.6% vs Q4 2019 Net Income-$1.74M-$1.74MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,653,000−11.8% Operating Incomederived-$3,224,000N/M Operating Cash Flowderived-$3,591,000N/M Free Cash Flowderived-$3,711,000N/M Margins · derivedGross margin38.3%−4.4 pt vs Q4 2019
Operating margin-74.8%−13.1 pt vs Q4 2019
Net margin-40.3%+33.3 pt vs Q4 2019
ended Mar 31, 2020 · filed Jul 10, 2020 · 101 d after period end